- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01718522
Registry of Use and Application of Sensor Augmented Pump (SAP) Therapy Under Daily Life Conditions (RANSuP)
The Application and Advantage of Sensor Augmented Pump (SAP) Therapy Under Daily Conditions (Registerstudie Zur Anwendung Und Nutzen Der Sensorunterstützten Pumpentherapie (SuP) Unter Alltagsbedingungen)(RANSuP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this registry is to reflect the daily practice with Sensor Augmented Pump (SAP) therapy usage in Type 1 Diabetes Mellitus (DM) patients treated with Medtronic insulin pumps (Paradigm VEO®) and continuous glucose monitoring systems in Germany. In addition, the aim is of this registry is to support:
- obtain reimbursement for SAP therapy in Germany
- building a platform (advisory committee) for discussion of SAP data.
- looking for deficits with implementation of glucose sensor data in diabetes therapy management and development of "follow-up education" materials.
This is a national multi-center, post-market non-interventional prospective study with CE marked and commercially available devices and consumables.
The study will be conducted from March 2012 to April 2013 in Germany. The duration of individual patient participation is 3 to 6 months.
Health outcomes will be measured in approximately 75 patients between 6-65 years old diagnosed with Type 1 DM over a period of at least 3 months in approximately 15 centers. The patients are under treatment of Paradigm VEO® without any additional insulin injections and use continuous glucose monitoring, or patients that are not using continuous glucose monitoring, but that are willing to start with SAP. The enrolled subjects have a first visit inquiring the status data (including upload of device data in CareLink software, Hemoglobin A1c (HbA1c) value measurement) without any intervention. Thereafter, the SAP therapy is optimized based on individual continuous glucose monitoring (CGM) data during a second visit one month later and then a last visit like the first visit in which the status will be determined.
Parameters of glycemic control will be measured, such as the frequency of hypoglycemia (glucose values ≤ 70 mg/dl), over a period of 30 days after the first patient's visit (Visit 1) and after the visit 2 when an adjustment of the therapy has been discussed with the patient based on the collected CGM results between the two first visits.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with signed informed consent
- Type 1 DM and has been on insulin pump therapy for at least 3 months prior to signature of the informed consent
- patients use CGM component as part as part of the continuous subcutaneous insulin infusion (CSII) therapy for a minimum of 1 month
Exclusion Criteria:
- participation in any other trial
- any disease or drug treatment that can interfere with the outcome of sensor usage
- using CGM in CSII < 3 days/week
- patients not willing to sign informed consent
- abuse of alcohol or drugs (exception of nicotine consumption)
- eating disorder, anorexia, bulimia or other mental disorders
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Intervention Group
Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number (n) of Excursions <70 mg/dl Per Sensor Day at Baseline and 3 Months
Time Frame: baseline and 3 months
|
baseline and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number (n) of Excursions <40 mg/dl Per Sensor Day at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Hemoglobin A1c (HbA1c) Values (%) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Interstitial Sensor Glucose Concentration (mg/dl) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Sensor Wearing Time (Sensor Days/Calendar Week) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Area Under the Curve (AUC) in Hypoglycemic Region (< 70mg/dl) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Area under the curve (AUC) in hypoglycemic region (< 70mg/dl) at baseline (1 month before the start of the study) and 3 months during the study.
|
Baseline and 3 months
|
Area Under the Curve (AUC) in Hyperglycemic Region (>140mg/dl) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Area under the curve (AUC) in hyperglycemic region (>140mg/dl) at baseline (1 month before the start of the study) and 3 months during the study.
|
Baseline and 3 months
|
Time in Hyperglycemic Region Per Sensor Day at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Number of Automatic Low Glucose Suspend (LGS) Activations in Daytime (6:00 - 22:00 Hrs) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Number of Automatic Low Glucose Suspend (LGS) Activations in Nighttime (22:00 - 6:00 Hrs) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
|
Interstitial Sensor Glucose Excursions After Meals (Amplitude of Excursions) at Baseline and 3 Months
Time Frame: Baseline and 3 months
|
Baseline and 3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Tsioli C, Danne T für die RANSuP-Studiengruppe. RANSuP-Registerstudie: Anwendung der Sensorunterstützten Pumpentherapie unter Alltagsbedingungen. Diabetologie und Stoffwechsel 2013; 8: S62
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEN_G_DB_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on sensor augmented pump (SAP)
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes MellitusUnited States, Italy
-
University of Ljubljana, Faculty of MedicineCompletedType 1 Diabetes MellitusSlovenia
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingGlucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic DiseaseChina
-
Jaeb Center for Health ResearchCompletedType 1 DiabetesUnited States, France, Israel, Italy
-
University of VirginiaRecruiting
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... and other collaboratorsCompletedType 1 Diabetes MellitusUnited States
-
University of VirginiaStanford UniversityCompleted
-
University of VirginiaDexCom, Inc.; Tandem Diabetes Care, Inc.; Virginia Research Investment FundCompletedCognitive Change | Type 1 Diabetes MellitusUnited States
-
University of VirginiaDexCom, Inc.; Tandem Diabetes Care, Inc.; Jaeb Center for Health ResearchCompleted
-
Daniel Chernavvsky, MD, CRCNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom...CompletedType 1 Diabetes MellitusUnited States